Cargando…
The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives
One of the main problems in chemotherapy using platinum drugs as anticancer agents is the resistance phenomenon. Synthesizing and evaluating valid alternative compounds is challenging. This review focuses on the last two years of progress in the studies of platinum (II)- and platinum (IV)-based anti...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144581/ https://www.ncbi.nlm.nih.gov/pubmed/37110640 http://dx.doi.org/10.3390/molecules28083407 |
_version_ | 1785034134340501504 |
---|---|
author | Coffetti, Giulia Moraschi, Martina Facchetti, Giorgio Rimoldi, Isabella |
author_facet | Coffetti, Giulia Moraschi, Martina Facchetti, Giorgio Rimoldi, Isabella |
author_sort | Coffetti, Giulia |
collection | PubMed |
description | One of the main problems in chemotherapy using platinum drugs as anticancer agents is the resistance phenomenon. Synthesizing and evaluating valid alternative compounds is challenging. This review focuses on the last two years of progress in the studies of platinum (II)- and platinum (IV)-based anticancer complexes. In particular, the research studies reported herein focus on the capability of some platinum-based anticancer agents to bypass resistance to chemotherapy, which is typical of well-known drugs such as cisplatin. Regarding platinum (II) complexes, this review deals with complexes in trans conformation; complexes containing bioactive ligands, as well as those that are differently charged, all experience a different reaction mechanism compared with cisplatin. Regarding platinum (IV) compounds, the focus was on complexes with biologically active ancillary ligands that exert a synergistic effect with platinum (II)-active complexes upon reduction, or those for which controllable activation can be realized thanks to intracellular stimuli. |
format | Online Article Text |
id | pubmed-10144581 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101445812023-04-29 The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives Coffetti, Giulia Moraschi, Martina Facchetti, Giorgio Rimoldi, Isabella Molecules Review One of the main problems in chemotherapy using platinum drugs as anticancer agents is the resistance phenomenon. Synthesizing and evaluating valid alternative compounds is challenging. This review focuses on the last two years of progress in the studies of platinum (II)- and platinum (IV)-based anticancer complexes. In particular, the research studies reported herein focus on the capability of some platinum-based anticancer agents to bypass resistance to chemotherapy, which is typical of well-known drugs such as cisplatin. Regarding platinum (II) complexes, this review deals with complexes in trans conformation; complexes containing bioactive ligands, as well as those that are differently charged, all experience a different reaction mechanism compared with cisplatin. Regarding platinum (IV) compounds, the focus was on complexes with biologically active ancillary ligands that exert a synergistic effect with platinum (II)-active complexes upon reduction, or those for which controllable activation can be realized thanks to intracellular stimuli. MDPI 2023-04-12 /pmc/articles/PMC10144581/ /pubmed/37110640 http://dx.doi.org/10.3390/molecules28083407 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Coffetti, Giulia Moraschi, Martina Facchetti, Giorgio Rimoldi, Isabella The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives |
title | The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives |
title_full | The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives |
title_fullStr | The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives |
title_full_unstemmed | The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives |
title_short | The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives |
title_sort | challenging treatment of cisplatin-resistant tumors: state of the art and future perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144581/ https://www.ncbi.nlm.nih.gov/pubmed/37110640 http://dx.doi.org/10.3390/molecules28083407 |
work_keys_str_mv | AT coffettigiulia thechallengingtreatmentofcisplatinresistanttumorsstateoftheartandfutureperspectives AT moraschimartina thechallengingtreatmentofcisplatinresistanttumorsstateoftheartandfutureperspectives AT facchettigiorgio thechallengingtreatmentofcisplatinresistanttumorsstateoftheartandfutureperspectives AT rimoldiisabella thechallengingtreatmentofcisplatinresistanttumorsstateoftheartandfutureperspectives AT coffettigiulia challengingtreatmentofcisplatinresistanttumorsstateoftheartandfutureperspectives AT moraschimartina challengingtreatmentofcisplatinresistanttumorsstateoftheartandfutureperspectives AT facchettigiorgio challengingtreatmentofcisplatinresistanttumorsstateoftheartandfutureperspectives AT rimoldiisabella challengingtreatmentofcisplatinresistanttumorsstateoftheartandfutureperspectives |